Rhenman & Partners Asset Management Ab Nurix Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 300,000 shares of NRIX stock, worth $5.47 Million. This represents 0.56% of its overall portfolio holdings.
Number of Shares
300,000
Previous 174,393
72.03%
Holding current value
$5.47 Million
Previous $3.64 Million
85.08%
% of portfolio
0.56%
Previous 0.36%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
180Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$124 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$78.1 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$73.2 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$70.8 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$70.6 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $860M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...